Innovent Biologics | Sustainability Performance
Biopharmaceutical company engaged in the discovery, development, and commercialization of biologic medicines
2011
China
5,001 - 10,000 employees
Pharmaceuticals
$1B - 10B in revenue
$100M - 500M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#8504
Overallⓘ#421
in Chinaⓘ#200
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon emissionsEnergy consumptionWater ManagementAir & land impactNature and biodiversitySocial
Diversity and InclusionPay GapsExternalitiesGovernance
SDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Leading
Critical
Intensity
Energy consumption (direct) intensity (MWh /$M)
Industry Benchmark
19.5
B/M 42.0
Powered by illuminem and GIST Impact
Controversy level
- Innovent Biologics Inc, Chinese biotech (Lilly Tyvyt PD-1 inhibitor partner), has faced sustained scrutiny over the historic 2022 US FDA Advisory Committee rejection of Tyvyt Sintilimab US application due to China-only clinical trials, plus the contested 2024 sustained share price volatility amid US-China biotech decoupling pressure affecting Hong Kong-listed institutional shareholders.
